179 related articles for article (PubMed ID: 31419930)
1. An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Yang Q; Yao Y; Li K; Jiao L; Zhu J; Ni C; Li M; Dou QP; Yang H
Curr Pharm Des; 2019; 25(30):3248-3256. PubMed ID: 31419930
[TBL] [Abstract][Full Text] [Related]
2. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram's Anticancer Activity: Evidence and Mechanisms.
Jiao Y; Hannafon BN; Ding WQ
Anticancer Agents Med Chem; 2016; 16(11):1378-1384. PubMed ID: 27141876
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram: a novel repurposed drug for cancer therapy.
Lu C; Li X; Ren Y; Zhang X
Cancer Chemother Pharmacol; 2021 Feb; 87(2):159-172. PubMed ID: 33426580
[TBL] [Abstract][Full Text] [Related]
5. Disulfiram: A novel repurposed drug for cancer therapy.
Zeng M; Wu B; Wei W; Jiang Z; Li P; Quan Y; Hu X
Chin Med J (Engl); 2024 Jan; ():. PubMed ID: 38275022
[TBL] [Abstract][Full Text] [Related]
6. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Disulfiram as a Chemo-Therapeutic Sensitizer: Molecular Targets and Mechanisms.
Sun F; Wang H; Nie J; Hong B
Anticancer Agents Med Chem; 2022; 22(17):2920-2926. PubMed ID: 35430981
[TBL] [Abstract][Full Text] [Related]
8. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
9. Disulfiram as a Therapeutic Agent for Metastatic Malignant Melanoma-Old Myth or New Logos?
Meraz-Torres F; Plöger S; Garbe C; Niessner H; Sinnberg T
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33260923
[TBL] [Abstract][Full Text] [Related]
10. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
11. Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy.
McMahon A; Chen W; Li F
J Control Release; 2020 Mar; 319():352-359. PubMed ID: 31911155
[TBL] [Abstract][Full Text] [Related]
12. Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines.
Yang Z; Guo F; Albers AE; Sehouli J; Kaufmann AM
Biomed Pharmacother; 2019 May; 113():108727. PubMed ID: 30870721
[TBL] [Abstract][Full Text] [Related]
13. Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes.
Hassani S; Ghaffari P; Chahardouli B; Alimoghaddam K; Ghavamzadeh A; Alizadeh S; Ghaffari SH
Biomed Pharmacother; 2018 Mar; 99():561-569. PubMed ID: 29902866
[TBL] [Abstract][Full Text] [Related]
14. The combination of disulfiram and copper for cancer treatment.
Li H; Wang J; Wu C; Wang L; Chen ZS; Cui W
Drug Discov Today; 2020 Jun; 25(6):1099-1108. PubMed ID: 32320854
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Li L; Yang H; Chen D; Cui C; Dou QP
Toxicol Appl Pharmacol; 2008 Jun; 229(2):206-14. PubMed ID: 18304598
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
17. Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens.
Lu Y; Pan Q; Gao W; Pu Y; Luo K; He B; Gu Z
Biomaterials; 2022 Feb; 281():121335. PubMed ID: 34979419
[TBL] [Abstract][Full Text] [Related]
18. Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation.
Wang K; Michelakos T; Wang B; Shang Z; DeLeo AB; Duan Z; Hornicek FJ; Schwab JH; Wang X
Cancer Lett; 2021 May; 505():37-48. PubMed ID: 33582212
[TBL] [Abstract][Full Text] [Related]
19. Advancing Cancer Therapy with Copper/Disulfiram Nanomedicines and Drug Delivery Systems.
Kang X; Jadhav S; Annaji M; Huang CH; Amin R; Shen J; Ashby CR; Tiwari AK; Babu RJ; Chen P
Pharmaceutics; 2023 May; 15(6):. PubMed ID: 37376016
[TBL] [Abstract][Full Text] [Related]
20. A binuclear complex constituted by diethyldithiocarbamate and copper(I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts.
Han J; Liu L; Yue X; Chang J; Shi W; Hua Y
Toxicol Appl Pharmacol; 2013 Dec; 273(3):477-83. PubMed ID: 24060341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
